Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00260611 | Study of Oxaliplatin and Taxotere in Prostate Cancer | PHASE2 | COMPLETED | 34 | — | — | Nov 1, 2004 | Sep 1, 2007 | Mar 25, 2015 | 1 | United States |
Subjects once off treatment wil be followed for survival
| Arm | Type | Description |
|---|---|---|
| Oxaliplatin and Taxotere | EXPERIMENTAL | Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or \>50% increase in serum PSA. |
| Name | Type | Description |
|---|---|---|
| Oxaliplatin | DRUG | - |
| Taxotere | DRUG | - |
Inclusion Criteria: Must have histologically or cytologically confirmed adenocarcinoma consistent clinically and histologically with carcinoma of the prostate Confirmed androgen independent prostate cancer (progression despite castrate levels of serum testosterone) Measurable or evaluable disease (...